Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this clinical-stage biotech company that develops stem cell treatments would post a loss of $0.57 per share when it actually produced a loss of $0.45, delivering a surprise of 21.05%.Over the last four quarters, the company has surpassed consensus EPS es ...